Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Recruiting now · Phase 1

Conditions studied: Clear Cell Renal Cell Carcinoma

In brief

The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).

Key facts

Study ID

NCT05433142

Run by

Xencor, Inc.

People needed

307

Starts

2022-06-13

Expected to finish

2028-12-01

Last updated by the study team

2026-08-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as assessed by the local site investigator. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
• Subjects who have relapsed and refractory ccRCC, pRCC, NSCLC, and CRC with evidence of disease progression on standard-of-care therapies
• ECOG performance status of 0 or 1.
• All subjects must have adequate tumor sample available (slides or archival FFPE blocks)

You may not qualify if…

• Prior treatment with an investigational anti-ENPP3/CD203c therapy
• History of serious allergic or anaphylactic/hypersensitivity reaction to monoclonal antibody therapy
• Systemic antineoplastic therapy within 5 half-lives on the first dose of study treatment.
• Failure to recover from any clinically significant toxicity related to previous anticancer treatment
• Have known active central nervous system metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are radiologically stable,
• Active known autoimmune disease (except that subjects are permitted to enroll if they have vitiligo; type 1 diabetes mellitus; residual hypothyroidism due to an autoimmune condition that is treatable with hormone replacement therapy only; psoriasis, atopic dermatitis, or another autoimmune skin condition that is managed without systemic therapy; or arthritis that is managed without systemic therapy beyond oral acetaminophen and nonsteroidal anti-inflammatory drugs)
• Evidence of any serious infection requiring IV anti-infective treatment within 14 days prior to the first dose of study drug
• Have a known additional malignancy that is progressing or has required active treatment within the past 2 years

Where it is running

• Xencor Investigative Site — Phoenix, Arizona, United States (enrolling)
• Xencor Investigative Site — Duarte, California, United States (enrolling)
• Xencor Investigative Site — Sacramento, California, United States (enrolling)
• Xencor Investigative Site — New Haven, Connecticut, United States (enrolling)
• Xencor Investigative Site — Jacksonville, Florida, United States (enrolling)
• Xencor Investigative Site — Atlanta, Georgia, United States (enrolling)
• Xencor Investigative Site — Chicago, Illinois, United States (enrolling)
• Xencor Investigative Site — Chicago, Illinois, United States (enrolling)
• Xencor Investigative Site — Louisville, Kentucky, United States (enrolling)
• Xencor Investigative Site — Rochester, Minnesota, United States (enrolling)
• Xencor Investigative Site — New Brunswick, New Jersey, United States (enrolling)
• Xencor Investigative Site — New York, New York, United States (enrolling)
• Xencor Investigative Site — New York, New York, United States (enrolling)
• Xencor Investigative Site — Charlotte, North Carolina, United States (enrolling)
• Xencor Investigative Site — Durham, North Carolina, United States (enrolling)
• Xencor Investigative Site — Cincinnati, Ohio, United States (enrolling)
• Xencor Investigative Site — Columbus, Ohio, United States (enrolling)
• Xencor Investigative Site — Oklahoma City, Oklahoma, United States (enrolling)
• Xencor Investigative Site — Nashville, Tennessee, United States (enrolling)
• Xencor Investigative Site — Seattle, Washington, United States (enrolling)
• Xencor Investigative Site — Leuven, Belgium (enrolling)
• Xencor Investigative Site — Bourdeaux, France (enrolling)
• Xencor Investigative Site — Villejuif, France (enrolling)
• Xencor Investigative Site — Barcelona, Spain (enrolling)
• Xencor Investigative Site — Madrid, Spain (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.